In the setting of early BC, neoadjuvant chemotherapy (NAC) preceding surgical excision of residual tumor tissue remains a cornerstone of the treatment of this malignancy and strategies to improve the clinical efficacy and safety of this pre-operative procedure are ongoing, including evaluation of the combination of co-inhibitory PD-L1-targeted immunotherapy with chemotherapy (15). The gene discussed is CD274; the disease is breast cancer.